Topical praziquantel as a new treatment for perioral dermatitis: results of a randomized vehicle-controlled pilot study

Autor:	Anand Jillella, M. R. Bribeche, V. V. Gladichev, V. P. Fedotov, D. M. Pukhalskaya
Rok vydání:	2014
Předmět:	Adult Male medicine.medical_specialty Adolescent Administration Topical Anti-Inflammatory Agents Pilot Projects Dermatology Placebo Praziquantel law.invention Young Adult Randomized controlled trial Quality of life law Perioral dermatitis parasitic diseases Medicine Humans Single-Blind Method Dermatitis Perioral Young adult Adverse effect business.industry Middle Aged medicine.disease Tolerability Quality of Life Female business medicine.drug Follow-Up Studies
Zdroj:	Clinical and experimental dermatology. 39(4)
ISSN:	1365-2230
Popis:	Summary Background Perioral dermatitis (POD) is a common skin disease, and extending the range of treatments available for this condition is important. Aim To evaluate the safety, efficacy and tolerability of praziquantel 3% ointment as monotherapy. Methods This was a single-centre, randomized, single-blind, vehicle-controlled pilot study in adult patients (n = 46) with 4 weeks of treatment and 4 weeks of follow-up. Efficacy was assessed clinically using the Investigator's Global Assessment (IGA) and the Perioral Dermatitis Severity Index (PODSI). Quality of life (QOL) was determined by the Dermatology Quality of Life Index (DLQI). Results PODSI was significantly lower in the praziquantel group than in the placebo (vehicle) group, both during treatment and period. Mean IGA score showed a statistically significant therapeutic advantage of praziquantel over placebo at week 4 (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734835d962a34cd7b21a4c269554a9db https://pubmed.ncbi.nlm.nih.gov/24825135 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.